Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
Denis Kimathi, Fawzia Butt, Symon Guthua, Wairimu Waweru
KEY CLINICAL MESSAGE: Medication-related osteonecrosis of the Jaw (MRONJ) is a rare complication of the jaws following the administration of antiresorptive or antiangiogenic drugs. This condition poses a major challenge to its management. Its prevention and management need a multidisciplinary collaboration. We described three patients with MRONJ including their presentation, investigations, management protocols, and outcomes. A brief appraisal of the literature on MRONJ was also done...
April 2024: Clinical Case Reports
#2
JOURNAL ARTICLE
Opinder Sahota, Melanie Narayanasamy, Anastasios Bastounis, Zoe Paskins, Simon Bishop, Tessa Langley, Neil Gittoes, Sarah Davis, Ann Baily, Moira Holmes, Jo Leonardi-Bee
BACKGROUND: Bisphosphonates are a class of medication commonly used to treat osteoporosis. Alendronate is recommended as the first-line treatment; however, long-term adherence (both treatment compliance and persistence) is poor. Alternative bisphosphonates are available, which can be given intravenously and have been shown to improve long-term adherence. However, the most clinically effective and cost-effective alternative bisphosphonate regimen remains unclear. What is the most cost-effective bisphosphonate in clinical trials may not be the most cost-effective or acceptable to patients in everyday clinical practice...
April 2024: Health Technology Assessment: HTA
#3
JOURNAL ARTICLE
Salvatore Minisola, Cristiana Cipriani, Luciano Colangelo, Jessica Pepe
A 47-year-old postmenopausal woman with osteoporosis was treated with denosumab, which was discontinued due to side effects. She was therefore transitioned to a yearly intravenous infusion of zoledronic acid. An increase in bone turnover markers together with bone loss at the lumbar spine was observed before the second infusion, suggesting an overshooting of bone resorption due to denosumab discontinuation. On physical examination, the patient was restless and reported having lost about 10 kg since the last visit...
March 4, 2024: Journal of Bone and Mineral Research
#4
RANDOMIZED CONTROLLED TRIAL
Janet Brown, Margaret A Paggiosi, Emma Rathbone, Walter Gregory, Gian Bertelli, Omar Din, Eugene McCloskey, David Dodwell, David Cameron, Richard Eastell, Robert Coleman
Adjuvant bisphosphonates are often recommended in postmenopausal women with early breast cancer at intermediate-to-high risk of disease recurrence, but the magnitude and duration of their effects on bone mineral density (BMD) and bone turnover markers (BTMs) are not well described. We evaluated the impact of adjuvant zoledronate on areal BMD and BTMs in a sub-group of patients who had completed the large 5-yr randomized Adjuvant Zoledronic Acid to Reduce Recurrence (AZURE) trial. About 224 women (recurrence free) who had completed the AZURE trial within the previous 3 mo were recruited from 20 UK AZURE trial sites...
March 4, 2024: Journal of Bone and Mineral Research
#5
JOURNAL ARTICLE
Mustafa Isleyen, Muge Cina, Halil Asci, Ilter Ilhan, Ramazan Oguz Yuceer
BACKGROUND: Medication-related osteonecrosis of the jaw (MRONJ) is a condition that can occur primarily in patients undergoing or have previously undergone therapy with bisphosphonates, particularly in the presence of risk factors, such as tooth extraction (TE). PURPOSE: This study aimed to evaluate the effect of selenium (SEL) administration on the prevention of osteonecrosis of the jaw in an MRONJ animal model. STUDY DESIGN, SETTING, AND SAMPLE: This study was a longitudinal in vivo animal study using a TE model in a sample of 48 Wistar rats...
March 28, 2024: Journal of Oral and Maxillofacial Surgery
#6
JOURNAL ARTICLE
Leila Pisheh, Serena Matis, Martina Taglieri, Linda Di Gregorio, Roberto Benelli, Alessandro Poggi
Antibody--drug conjugates (ADCs) are a promising delivery system that involves linking a monoclonal antibody (mAb) to a specific drug, such as a cytotoxic agent, to target tumor cells. This new class of antitumor therapy acts as a "biological missile" that can destroy tumor cells while increasing the therapeutic index and decreasing toxicity. One of the most critical factors in ADC design is selecting a target antigen that is highly expressed on the surface of cancer cells. In this study, we conjugated Cetuximab (Cet), a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), to aminobisphosphonates (N-BPs) such as ibandronate (IBA) or risedronate (RIS) or zoledronate (ZA)...
March 22, 2024: Cancers
#7
JOURNAL ARTICLE
Seong Son, Michael Y Oh, Byung-Rhae Yoo, Han-Byeol Park
Background : The comparison of the efficacy of zoledronate and denosumab for treating osteoporosis is controversial, and few randomized controlled trials have compared these two drugs in practical patients with acute osteoporotic vertebral compression fractures (OVCFs). We conducted a randomized controlled study to compare the efficacy of zoledronate and denosumab in patients with acute OVCF, with a focus on the occurrence of new OVCF. Methods : We enrolled 206 subjects who had their first acute OVCF, without any previous history of osteoporosis medication...
April 1, 2024: Journal of Clinical Medicine
#8
JOURNAL ARTICLE
Giorgia Grassi, Alberto Ghielmetti, Marta Zampogna, Iacopo Chiodini, Maura Arosio, Giovanna Mantovani, Cristina Eller Vainicher
BACKGROUND: After Denosumab (Dmab) discontinuation C-terminal telopeptide (CTX) levels increase, bone mineral density (BMD) decreases and multiple vertebral fractures (FX) may occur with relevant impact on women's health. A sequential therapy with bisphosphonates is recommended and the European Calcified Tissue Society (ECTS) proposed repeated zoledronate (ZOL) administrations in patients with persistently high CTX levels, although the efficacy of this schedule is unknown. In this retrospective study we describe BMD changes and FX rate in 52 patients managed according to the ECTS recommendations...
April 13, 2024: Journal of Clinical Endocrinology and Metabolism
#9
JOURNAL ARTICLE
Ming-Kai Hsieh, Chi-Yun Wang, Fu-Cheng Kao, Hui-Ting Su, Mei-Feng Chen, Tsung-Ting Tsai, Po-Liang Lai
Nonunion resulting from early bone resorption is common after bone transplantation surgery. In these patients, instability or osteoporosis causes hyperactive catabolism relative to anabolism, leading to graft resorption instead of fusion. Systemic zoledronate administration inhibits osteoclastogenesis and is widely used to prevent osteoporosis; however, evidence on local zoledronate application is controversial due to osteoblast cytotoxicity, uncontrolled dosing regimens, and local release methods. We investigated the effects of zolendronate on osteoclastogenesis and osteogenesis and explored the corresponding signaling pathways...
May 2024: JBMR Plus
#10
JOURNAL ARTICLE
Mafo Kamanda-Kosseh, Stephanie Shiau, Sanchita Agarwal, Ananya Kondapalli, Ivelisse Colon, Nayoung Kil, Mariana Bucovsky, Joan M Lappe, Julie Stubby, Elizabeth Shane, Adi Cohen
CONTEXT: We previously reported that sequential teriparatide followed by denosumab substantially increases BMD in premenopausal idiopathic osteoporosis (PremenIOP). OBJECTIVE: To determine whether administration of bisphosphonates after denosumab cessation is associated with stable BMD in PremenIOP. DESIGN: Open-label extension study. PARTICIPANTS: 24 PremenIOP Teriparatide-Denosumab Study participants. INTERVENTIONS: Oral alendronate (ALN), 70mg weekly, or IV zoledronic acid (ZOL), 5mg once (patient choice), was administered 7 months (M) after final denosumab dose...
April 12, 2024: Journal of Clinical Endocrinology and Metabolism
#11
REVIEW
Andrey Soares, Fernando Sabino Marques Monteiro, Karine Martins da Trindade, Adriano Gonçalves E Silva, Ana Paula Garcia Cardoso, André Deeke Sasse, André P Fay, André Paternò Castello Dias Carneiro, Antonio Machado Alencar Junior, Augusto César de Andrade Mota, Bruno Santucci, Daniel da Motta Girardi, Daniel Herchenhorn, Daniel Vilarim Araújo, Denis Leonardo Jardim, Diogo Assed Bastos, Diogo Rodrigues Rosa, Fabio A Schutz, Fábio Roberto Kater, Felipe da Silva Marinho, Fernando Cotait Maluf, Fernando Nunes Galvão de Oliveira, Fernando Vidigal, Igor Alexandre Protzner Morbeck, Jose Augusto Rinck Júnior, Leonardo Atem G A Costa, Manuel Caitano Dias Ferreira Maia, Manuela Zereu, Marcelo Roberto Pereira Freitas, Mariane Sousa Fontes Dias, Milena Shizue Tariki, Pamela Muniz, Patrícia Medeiros Milhomem Beato, Paulo Sérgio Moraes Lages, Pedro Isaacsson Velho, Ricardo Saraiva de Carvalho, Rodrigo Coutinho Mariano, Sandro Roberto de Araújo Cavallero, Thiago Martins Oliveira, Vinicius Carrera Souza, Oren Smaletz, Stênio de Cássio Zequi
PURPOSE: Renal cell carcinoma is an aggressive disease with a high mortality rate. Management has drastically changed with the new era of immunotherapy, and novel strategies are being developed; however, identifying systemic treatments is still challenging. This paper presents an update of the expert panel consensus from the Latin American Cooperative Oncology Group and the Latin American Renal Cancer Group on advanced renal cell carcinoma management in Brazil. METHODS: A panel of 34 oncologists and experts in renal cell carcinoma discussed and voted on the best options for managing advanced disease in Brazil, including systemic treatment of early and metastatic renal cell carcinoma as well as nonclear cell tumours...
April 9, 2024: Journal of Cancer Research and Clinical Oncology
#12
JOURNAL ARTICLE
Forrest L Baker, Kyle A Smith, Preetesh L Mylabathula, Tiffany M Zuniga, Douglass M Diak, Helena Batatinha, Grace M Niemiro, Michael D Seckeler, Charles R Pedlar, Daniel P O'Connor, Jamie N Colombo, Emmanuel Katsanis, Richard J Simpson
Exercise mobilizes cytotoxic lymphocytes to blood which may allow superior cell products to be manufactured for cancer therapy. Gamma-Delta (γδ) T-cells have shown promise for treating solid tumors, but there is a need to increase their potency against hematologic malignancies. Here, we show that human γδ T-cells mobilized to blood in response to just 20-minutes of graded exercise have surface phenotypes and transcriptomic profiles associated with cytotoxicity, adhesion, migration and cytokine signaling...
April 9, 2024: Cancer Res Commun
#13
Liyuan Shang, Weizhe Shi, Yibo Xu, Tianying Nong, Xia Li, Zhaohui Li, Yanhan Liu, Jingchun Li, Ya-Ping Tang, Mingwei Zhu, Hongwen Xu
BACKGROUND: Bruck syndrome (BS) is an extremely rare autosomal-recessive connective tissue disorder mainly characterized by bone fragility, congenital joint contracture, and spinal deformity. It is also considered as a rare form of osteogenesis imperfecta (OI) due to features of osteopenia and fragility fractures. Its two forms, BS1 and BS2, are caused by pathogenic variations in FKBP10 and PLOD2 , respectively. OBJECTIVE: We aimed to improve the clinical understanding of BS by presenting a case from China and to identify the genetic variants that led to this case...
April 15, 2024: Heliyon
#14
JOURNAL ARTICLE
Vanessa Costa de Sousa, Fátima Regina Nunes Sousa, Raquel Felipe Vasconcelos, Gisele Angelino Barreto, Conceição S Martins, Nilson Romero Dias, Sislana Costa, Maria Jennifer Chaves Bernardino, George de Almeida Silva, Nadine Linhares, Delane Gondim, Mirna Marques, Helliada Chaves, Karuza Alves, Renata Leitão, Gerly A C Brito, Maria Elenir Nobre Pinho Ribeiro, Paula Goes
To investigate de effect of PAb gel on the bone tissue of rats submitted to Bisphosphonate-related osteonecrosis of the jaws (BRONJ). Initially, 54 animals were submitted to BRONJ model by Zoledronic Acid (ZA) (0.1 mg/kg 3x/wk for 9 wk, ip), followed by the 1st upper left molar extraction at the 8th wk. After tooth removal, the animals were divided into 3 groups, ZA that received placebo gel or PAb gel that received 1% PAb gel, inside the dental alveolus. The control Group (CONTROL) received 0.1 mg/kg of 0...
April 8, 2024: Scientific Reports
#15
Ashutosh Lohiya, Nareshkumar Dhaniwala, Shivshankar Jadhav, Siddharth K Patel, Saksham Goyal
Giant cell tumors are benign yet locally aggressive neoplasms commonly observed in the distal radius, exhibiting higher recurrence rates compared to other tumor types. This study presents a case involving a 50-year-old farmer who presented with swelling at the distal end of his wrist. The patient underwent treatment involving intralesional curettage and supplementation with zoledronic acid, resulting in a significant reduction in the tumor's potential for recurrence. This approach aims to achieve an optimal balance between functional outcomes and disease management in the majority of cases...
March 2024: Curēus
#16
JOURNAL ARTICLE
Xiang Li, Sara Martinez-Ramos, Freija T Heedge, Andrew Pitsillides, George Bou-Gharios, Blandine Poulet, Chantal Chenu
Osteoarthritis (OA) is characterised by the deterioration of cartilage in the joints and pain. We hypothesise that semaphorin-3A (sema-3A), a chemorepellent for sensory nerves, plays a role in joint degradation and pain. We used the mechanical joint loading (MJL) model of OA to investigate sema-3A expression in the joint and examine its association with the development of OA and pain. We also analyse its effect on chondrocyte differentiation using the ATDC5 cell line. We demonstrate that sema-3A is present in most tissues in the healthy joint and its expression increases in highly innervated tissues, such as cruciate ligaments, synovial lining and subchondral bone, in loaded compared to nonloaded control joints...
April 2024: Cell Biochemistry and Function
#17
JOURNAL ARTICLE
Yusuke Inoue, Asuka Oda, Yusaku Maeda, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Tomoko Maruhashi, Mamiko Takahashi, Shiro Fujii, Shingen Nakamura, Hirokazu Miki, Masahiro Hiasa, Jumpei Teramachi, Takeshi Harada, Masahiro Abe
As multiple myeloma (MM) progresses, immune effector cells decrease in number and function and become exhausted. This remains an insurmountable clinical issue that must be addressed by development of novel modalities to revitalize anti-MM immunity. Human Vγ9Vδ2 T (Vδ2+ γδ T) cells serve as the first line of defense against pathogens as well as tumors and can be expanded ex vivo from peripheral blood mononuclear cells (PBMCs) upon treatment with amino-bisphosphonates in combination with IL-2...
April 6, 2024: International Journal of Hematology
#18
Qinguo Liu, Ying Zhang, Deshou Ma, Huazhen Gengzhi, Yusufu Maimaiti, Qishuai Chen, Zhijun Ma
BACKGROUND: Parathyroid carcinoma (PC) is a rare endocrine malignancy causing pathological changes such as abnormal bone metabolism, elevated serum calcium, and impaired renal function, and uncontrollable hypercalcemia is the main cause of death in PC patients. The diagnosis of PC is challenging and relying on postoperative histopathology. Radical surgery at the first time is the only effective therapy to cure PC. Hungry bone syndrome (HBS) is a relatively uncommon complication of parathyroidectomy characterized by profound and prolonged hypocalcemia, timely electrolyte monitoring and alternative interventional protocols can prevent symptomatic hypocalcemia...
April 2024: Cancer reports
#19
Yeung-Ae Park, Walter E Plehwe, Kapilan Varatharajah, Sophie Hale, Michael Christie, Christopher J Yates
UNLABELLED: Skeletal fluorosis is rare and occurs secondary to chronic high amounts of fluoride consumption, manifesting as diffuse osteosclerosis, skeletal pain, connective tissue calcification, and increased fracture risk. Methoxyflurane is a volatile, fluorinated hydrocarbon-inhaled analgesic, and the maximum recommended dose is 15 mL (99.9 % w/w) per wk. A rodent study found increased skeletal fluoride after methoxyflurane exposure. However, skeletal fluorosis secondary to methoxyflurane use in humans has rarely been reported...
May 2024: JBMR Plus
#20
JOURNAL ARTICLE
Sangeet Kumar Agarwal, Jyoti Agarwal, Arushi Gupta, Vijay Bhushan Dutta
Giant cell tumor is locally aggressive primary benign neoplasm of bone with tendency of frequent recurrence, metastasis and malignant transformation. Because of the rarity of the disease involving mandible, no definite treatment guideline is established. Surgical treatment is the treatment of choice for giant cell tumor. Due to its proximity to vital structures including skull base, the recurrent disease associated with less invasive procedure could be difficult to manage while more invasive procedure will result in higher morbidity and complex reconstruction...
April 2024: Indian Journal of Otolaryngology and Head and Neck Surgery
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
